Antares Pharma Inc (NASDAQ:ATRS)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $3.23, but opened at $3.30. Antares Pharma shares last traded at $3.42, with a volume of 2754600 shares changing hands.

A number of equities analysts have weighed in on ATRS shares. BidaskClub raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 24th. ValuEngine raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, August 8th. Finally, HC Wainwright set a $4.00 target price on shares of Antares Pharma and gave the company a “buy” rating in a research note on Wednesday, August 8th.

The company has a market cap of $538.43 million, a price-to-earnings ratio of -30.46 and a beta of 0.34. The company has a current ratio of 2.33, a quick ratio of 1.89 and a debt-to-equity ratio of 1.01.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01). Antares Pharma had a negative net margin of 35.53% and a negative return on equity of 64.96%. The firm had revenue of $14.16 million for the quarter, compared to analysts’ expectations of $13.70 million. equities analysts predict that Antares Pharma Inc will post -0.1 earnings per share for the current fiscal year.

In other news, CEO Robert F. Apple sold 43,000 shares of the stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $3.75, for a total transaction of $161,250.00. Following the sale, the chief executive officer now owns 1,573,562 shares in the company, valued at $5,900,857.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jacques Gonella sold 49,507 shares of the stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $3.09, for a total transaction of $152,976.63. Following the sale, the director now owns 9,985,848 shares in the company, valued at approximately $30,856,270.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 343,000 shares of company stock worth $1,088,250. Corporate insiders own 12.20% of the company’s stock.

Large investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY grew its holdings in shares of Antares Pharma by 127.0% during the second quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $133,000 after buying an additional 28,875 shares during the last quarter. MetLife Investment Advisors LLC boosted its holdings in Antares Pharma by 281.1% in the first quarter. MetLife Investment Advisors LLC now owns 71,731 shares of the specialty pharmaceutical company’s stock worth $158,000 after purchasing an additional 52,911 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Antares Pharma by 533.6% in the first quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock worth $987,000 after purchasing an additional 377,824 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Antares Pharma by 17.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 711,562 shares of the specialty pharmaceutical company’s stock worth $1,566,000 after purchasing an additional 104,733 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in Antares Pharma in the first quarter worth approximately $1,959,000. Hedge funds and other institutional investors own 38.92% of the company’s stock.

About Antares Pharma (NASDAQ:ATRS)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Read More: What is Compound Annual Growth Rate (CAGR)?

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.